Drug intelligence / Profile preview

Revimmune

Development stage: Unknown
Lead developer: Accentia Biopharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

**Revimmune** is a proprietary high-dose, pulsed intravenous regimen of **cyclophosphamide** (branded as Cytoxan®), developed based on research from Johns Hopkins University to treat severe, refractory autoimmune diseases. It works by inducing profound lymphodepletion, effectively "rebooting" the patient's immune system to achieve durable remissions without ongoing immunosuppression. Accentia Biopharmaceuticals holds the worldwide exclusive license from Johns Hopkins and Revimmune LLC, with strategic supply from Baxter Healthcare; it has shown high remission rates in over 200 patients across various autoimmune conditions and received FDA Orphan Drug Designation, with plans for Phase 3 trials in multiple sclerosis.[3][5][6][7]

Brand names: Revimmune

Targets

DNA

Beyond the preview

Go deeper on Revimmune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revimmune.

Explore the full profile